Botox may be safe and effective for the treatment of gastric cancer
the ONA take:
According to an international study, researchers from the Germany, Japan, Norway, and the United States have found that Botox may be an effective treatment for gastric cancer.
The researchers were studying the role of the nervous system in cancer growth and discovered that the vagal nerve releases acetylcholine which contributes to the growth of gastric cancer.
The team then began testing methods that would inhibit the release of acetylcholine in order to halt the growth of the tumor. They tested four methods: severing the gastric vagus nerve, injecting Botox to inhibit the release of the neurotransmitter, administered a drug to stop the neurotransmitter from binding to its receptors, and blocking the receptor gene. The team found that the first two methods were the most effective at inhibiting tumor growth.
Because Botox is cheaper and safer than most standard chemotherapy used to treat gastric cancer, treatment with Botox is promising; however, the researchers suggest that Botox should only be used as adjuvant treatment after a patient no longer responds to chemotherapy or chooses to avoid chemotherapy. The researchers hope to continue studying their discovery with a phase 2 clinical trial in patients with gastric cancer in Norway.
Researchers found that the vagal nerve contributes to the growth of gastric tumors.
In the study, researchers from Norway, Japan, Germany and the US investigated the role of the nervous system in cancer.
They found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.
In order to restrict tumor growth, the team began testing methods that would prevent this nerve from signaling to the tumor. "We found that by removing the effect of the nerve, the stem cells in the cancer tumor are suppressed, leading to cancer treatment and prevention," says Prof. Duan Chen, of the Norwegian University of Science and Technology.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|